A study to investigate Biomarker Effects of Pre-Surgical Treatment with DNA Damage Repair (DDR) Agents in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC).

Trial Identifier: D5330C00007
Sponsor: AstraZeneca
NCTID:: NCT03022409
Start Date: September 2017
Primary Completion Date: January 2021
Study Completion Date: January 2021
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
French Version
Chinese (Taiwan) Version

Trial Locations

Country Location
France Toulouse, France, 31300
Taiwan Changhua City, Taiwan, 50006
Taiwan Taipei, Taiwan, 100
United Kingdom London, United Kingdom, SE1 9RT
United States of America, PA Pittsburgh, PA, United States of America, 15213
United States of America, PA Pittsburgh, PA, United States of America, 15261